Related Experiment Videos
[News in oral antidiabetic therapy]
1Interní hematoonkologická klinika FN Brno, pracovistĕ Bohunice.
Vnitrni Lekarstvi
|November 22, 2001
Abstract:
In this article two new peroral antidiabetics are introduced. The first is repaglinide, a prandial glucose regulator. The second is rosiglitazone, a member of the thiazolidinediones family, which improves the sensitivity of tissues to insulin and reduces insulin resistance.